MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
0.6700
+0.0777
+13.12%
After Hours: 0.6800 +0.01 +1.49% 19:55 02/06 EST
OPEN
0.5907
PREV CLOSE
0.5923
HIGH
0.6800
LOW
0.5900
VOLUME
523.02K
TURNOVER
--
52 WEEK HIGH
25.75
52 WEEK LOW
0.5600
MARKET CAP
2.80M
P/E (TTM)
-0.0124
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at JAGX last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at JAGX last week (0119-0123)?
Weekly Report · 01/26 10:13
Jaguar Health Reduces Debt Through Equity Exchange with Iliad
Reuters · 01/26 07:44
Jaguar Health Executes Debt-Reducing Equity Warrant Transactions
TipRanks · 01/23 22:26
Jaguar Health highlights strategic focus on rare disease development program
TipRanks · 01/22 14:10
Jaguar Health Receives Orphan Drug Designation For Crofelemer In US/EU, Non-Dilutive Funding From Mytesi Out-License, Targeting SBS-IF And MVID As Potential Blockbuster Opportunity
Benzinga · 01/22 14:06
Jaguar Health to Present Rare Disease Pipeline at Sequire Investor Summit in Puerto Rico
Reuters · 01/22 14:00
More
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Webull offers Jaguar Health Inc stock information, including NASDAQ: JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.